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Abstract: Meroterpenoids are secondary metabolites formed due to mixed biosynthetic pathways 
which are produced in part from a terpenoid co-substrate. These mixed biosynthetically hybrid 
compounds are widely produced by bacteria, algae, plants, and animals. Notably amazing chemical 
diversity is generated among meroterpenoids via a combination of terpenoid scaffolds with polyke-
tides, alkaloids, phenols, and amino acids. This review deals with the isolation, chemical diversity, 
and biological effects of 452 new meroterpenoids reported from natural sources from January 2016 
to December 2020. Most of the meroterpenoids possess antimicrobial, cytotoxic, antioxidant, anti-
inflammatory, antiviral, enzyme inhibitory, and immunosupressive effects. 
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1. Introduction 
Natural products and their analogs in today’s age play a crucial role in the develop-
ment of novel drugs because of their tremendous structural diversity [1–5]. It has been 
reported that out of the 877 New Chemical Entities (NCEs) established between 1981 and 
2002, ca. 49% arose from natural products, or, synthetic molecules based on natural-prod-
uct-pharmacophores [6,7]. However, pharmaceutical research into natural secondary me-
tabolites has declined in the last two decades because of the difficulty in isolating com-
pounds with skeletally novel frameworks from natural resources rather than from combi-
natorial synthetic protocols [7–9].  
The term “meroterpenoid” was first used by Cornforth [10] in 1986 to describe natu-
ral products bearing a mixed terpenoid biogenesis. The prefix “mero-” is derived from the 
Greek word “merus” which means “fragment, or part, or partial” [11–13]. Meroterpenoids 
are thus a class of natural products derived from hybrid polyketide or non-polyketide and 
terpenoid biosynthesis. The unusual enzyme reactions responsible for connectivities 
among their structures, and their unique ring cores create a most interesting chemical di-
versity among meroterpenoids [11,14,15]. Interestingly, meroterpenoids are mostly re-
ported from fungi and marine organisms while only a limited number of meroterpenoids 
were obtained from plants [9].  
Ubiquinone-10, α-tocopherol and the anticancer drugs, viz., vinblastine and vincris-
tine are included in the meroterpenoid classification [12,13]. Due to the interesting chem-
ical diversity, meroterpenoids illustrated an impressive range of biological effects, viz., 
antioxidant [16–18], anti-inflammatory [19–22], anti-atherosclerotic [23], anti-adipogenic 
[24], anti-diabetic [25], anti-carcinogenic [26,27], and neuroprotective [28] activities. In 
2009, Geris and Simpson [12] published a review on fungal meroterpenoids. Peng and Qiu 
[13] reported on 135 meroterpenoids which were all obtained from the fungal genus 
Ganoderma sp. Quite recently, another four reviews appeared: (i) El-Demerdash et al. [29] 
summarized 320 meroterpenoids from marine fungi covering from 2009 to 2019. (ii) Zhao 
et al. [30] focused on terrestrial and marine-derived fungal 709 meroterpenoids (covered 
2009–2020). (iii) Gozari et al. [31] reviewed only 190 meroterpenoids from bacteria and 
fungi that showed significant preclinical effects. (iv) Jiang et al. [32] summarized the de-
scribed 1585 fungal meroterpenoids in 2009–2019.  
Our review article describes the systematic and complete summary of potentially bi-
oactive meroterpenoids from all natural sources except fungal meroterpenoids during the 
last five years 2016–2020 (January 2016 to December 2020). In point of fact, an amazing 
452 new meroterpenoids were discovered during this period, which were mostly tested 
for their various biological activities. 
2. Meroterpenoid Classification 
The structures of meroterpenoids are exceptionally diverse and complex which is 
why classifications of these compounds are not easy. Meroterpenoids were often classified 
in two ways. The first way is to classify these compounds as polyketide- and non-polyke-
tide-terpenoids previously described by Geris and Simpson [12]. The second way is to 
classify these compounds based on a common scaffold, common natural product skeleton, 
or heterocyclic ring system, viz., phloroglucinol, syncarpic acid, sesquiterpene, phthalide, 
benzofuran and phenylfuran [11,12]. We followed the second method. 
3. Phloroglucinol-Based Meroterpenoids 
Among other anticancer meroterpenoids, diformylphloroglucinol-derived mero-
terpenoids from Psidium guajava L. were identified by spectroscopic analyses and ECD 
calculations as psiguajavadials A (1) and B (2), and guajadial (3) (Figure 1) [33]. All these 
metabolites showed antitumor activity against HCT116, Huh7, DU145, CCRF-CEM, and 
A549 cells. (Table 1). Compounds 1 and 2 displayed dose-dependent inhibition of Top1 
activity [33]. Guajadial (3), inhibited endothelial cell proliferation and migration as well 
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as suppressing tumor growth in human NSCLC (A549 and H1650 cells) and xenograft 
mouse models. This potential has been reported as being a significant antineoplasmic ac-
tivity of 3. The Western blotting method to study the underlying mechanisms of VEGF 
receptor (VEGFR)2-mediated revealed that compound 3 inhibited A549 (IC50 = 3.58 μM) 
proliferation via blocking the Ras/MAPK pathway [34]; this activity of 3 is higher than the 
potential of cisplatin (IC50 value of 7.51), which was used as a positive control.  
 
Figure 1. Structures of phloroglucinol-based meroterpenoids 1–3. 
Diformylphloroglucinol-based meroterpenoids, viz., guajavadials A-C (4–6) (Figure 
2) were obtained from P. guajava and also exhibited cytotoxicity against A-549, HL-60, 
MCF-7, SMMC-7721, and SW480 cancer cell lines with IC50 values between 2.28–3.38 µM 
(Table 1). Compound 6 displayed the highest potential (IC50 = 3.54 µM) against SMMC-
7721 cell lines which is higher than the standard cisplatin (IC50 = 19.8 µM) [35]. The struc-
tures and activity differences revealed that the arrangement of the isoprene units is re-
sponsible for the activity potential, and thus the terpenoidal skeleton indeed plays a sig-
nificant role in the activity level, as can be seen in compounds 5 and 6 [35].  
Shang et al. [36] isolated a small range of cytotoxic formylphloroglucinol-derived 
meroterpenoids; the eucalrobusones A–I (7–15) (Figure 2) from Eucalyptus robusta. In the 
MTT assay, compound 7 moderately inhibited the growth of HepG2 (IC50: 18.5 μM) and 
U2OS (IC50: 45.0 μM), while metabolite 10 possesses a weaker potential against HepG2 
(26.7 μM) (Table 1). Compound 15 only exhibited moderate inhibition of U2OS cell lines 
with an IC50 value of 42.25 μM. Only metabolite 9 proved to be the most potent anticancer 
agent against the three target cancer cells with IC50: of 7.40 to 8.99. Activity of compound 
9 has been reported to be comparable to doxorubicin (IC50 = 5.23, 2.66 and 1.14 μM, re-
spectively). A study on the mechanism of action of compound 9 revealed that it signifi-
cantly inhibited cell division exerting cell proliferation on MCF-7 in a concentration de-
pendent manner. Eucalrobusones A (7) and B (8) bearing an unusual skeleton having a 
maaliane sesquiterpene core is linked to a phloroglucinol unit. On the other hand, the 
chroman ring in eucalrobusone E (11) is attached to a bicyclogermacrane unit at the C-
3/C-4 position. Meroterpenoid 12 bearing a phloroglucinol unit is linked to an aromatic 
dehydromenthane monoterpene group. Eucalrobusones G–I (13–15) are cubebane-based 
phloroglucinol-based meroterpenoids linked through a 1-oxaspiro[5.5]undecane unit [36]. 
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Figure 2. Structures of phloroglucinol-based meroterpenoids 4–15. 
Compounds (16–20) (Figure 3) were obtained from Eugenia umbelliflora belonging to 
the Myrtaceae family and tested for cytotoxic effects towards murine melanoma cells 
(B16F10 cell) and the leukemic cells (Nalm-6 cells and k562) (Table 1). Interestingly, com-
pound 18 displayed the highest cytotoxicity against K562 cells with an IC50 value of 0.38 
μM, while compounds 19 and eugenials E (20) exhibited inhibitory activity towards K562 
cells with IC50 values of 1.9 and 4.97 μM, respectively. Compounds 18–20 inhibited the 
growth of B16F10 cells with IC50 values of 6.0, 3.2 and 8.8 μM, respectively [37]. Eugenials 
C–E (18–20) showed lower inhibitory potential against Nalm-6 cells (Table 1). On the other 
hand, compound 16 (IC50 = 30.5 μM) has been reported to be more potent than 17 (IC50 = 
42.8 μM) against K562 cells (Table 1).  
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Figure 3. Structures of phloroglucinol-based meroterpenoids 16–25. 
Compounds 16 and 17 have fused phloroglucinol-monoterpene systems, while com-
pounds 18–20 do not have similar fused systems but only phloroglucinol-sesquiterpene 
attachments. Therefore, higher activity of compounds 18–20 can be attributed to the pres-
ence of the additional free phenol groups in their structures. Amongst eugenials C–E (18–
20), the other interesting factor affecting the activity level is their sesquiterpenyl deriva-
tives. Compound 18 (IC50 = 0.38 μM), which has a tricyclic aromadendrene core, enhances 
the activity of this compound by 5-fold and 13-fold respectively, which is encouragingly 
higher than compound 19 (IC50 = 1.9 μM) and compound 20 (IC50 = 4.97 μM) [37].  
Eucalyptus tereticornis is reported to produce formyl phloroglucinol meroterpenoids, 
since Liu et al. [38] isolated five formyl phloroglucinol-derived meroterpenoids viz., eu-
calteretials A–E (21–25). Besides spectroscopic analysis, ECD calculations were used to 
define the chirality of these compounds. At a concentration of 50 μM, compound 25 ex-
hibited comparable topoisomerase I (Top1) inhibitory activity to that of camptothecin, 
whereas, only compound 23 displayed growth inhibition of HCT116 cell lines with an IC50 
value of 4.8 μM (Table 1). Among compounds 21–25, both 21 and 22 are rare natural prod-
ucts in which the germacrene core unit and the phloroglucinol core are connected in a 
different pattern (Figure 3) [38].  
Eucalyptus globulus fruits are also rich in phloroglucinol-derived meroterpenoids, 
since several have been isolated previously. Indeed, Qin et al. [39] isolated 10 compounds 
from this source. The spectroscopic data and ECD calculations lead to their absolute struc-
ture determination as eucalypglobulusals A–J (26–35) (Figure 4) [39]. Eucalypglobulusal 
A (26) has an unusual structure bearing a phloroglucinol core coupled to a rearranged 
sesquiterpene skeleton. Among these compounds, eucalypglobulusal F (31) inhibited the 
growth of the human acute lymphoblastic cell line (CCRF-CEM) with an IC50 value of 3.3 
μM (Table 1), which is comparable with the positive control VP-16 (IC50 = 1.1 μM). How-
ever, the same compound was not active (IC50: > 10 μM) towards HCT116, DU145, Huh7 
Biomolecules 2021, 11, 957 6 of 56 
 
and A549. Moreover, eucalypglobulusal A (26) inhibited DNA topoisomerase I (Top1) 
[39].  
 
Figure 4. Structures of phloroglucinol-based meroterpenoids 26–35. 
Phloroglucinol-based meroterpenoids in the form of enantiomers viz., (±)-japonicols 
A–D (36a,b–39a,b) (Figure 5) were isolated from Hypericum japonicum. Moreover only 
compound 37a illustrated good KSHV activity (EC50: 8.75 μM; SI: 16.0) while the other 
compounds exhibited EC50 values of between 17.6 and 202.9 μM). Biosynthetically, it is 
suggested that these acylphloroglucinol-derived meroterpenoids are formed by non-en-
zymatic reactions, since all were isolated from H. japonicum in both enantiomeric forms 
[40].  
 
Figure 5. Structures of phloroglucinol-based meroterpenoids 36–39. 
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New acylphloroglucinol-based meroterpenoid enantiomers viz., (+)-japonicols E–H 
(40a/b–43a/b (Figure 6) have been reported from H. japonicum and their structures were 
established via extensive NMR and ECD techniques. Among these compounds, meroter-
penes 40a and 40b bore the rare ring unit, cyclopenta[b]chromene. Compounds 40a (IC50: 
8.30 μM; SI: 23.4) and 43a (IC50: 4.90 μM; SI: 25.7) exhibited inhibitory effects on KSHV 
(Table 1) [41]. On the other hand, the enantiomers of compounds 40a and 43a viz., 40b 
(IC50: 24.4 μM and 43b (IC50: 29.4 μM) were not especially that active towards KSHV. In 
addition compound 42b illustrated inhibitory effects with IC50: 6.7 μM and SI: 7.4 while 
the enantiomer, viz., compound 42a was not active (IC50: 21.3 μM). The authors believe 
this is illustrative that stereochemistry plays a definite role in enhancing KSHV inhibition. 
Notably, the activity of 42a is increased and the selectivity of 43a is due to the unique 
phenyl group at C-7′ [41].  
 
Figure 6. Structures of phloroglucinol-based meroterpenoids 40–43. 
Phosphodiesterase-4 (PDE4D-4) inhibitors; psiguajadials A–K (44–54) (Figure 7) were 
isolated from P. guajava. All these natural products have been reported to be significant 
inhibitors of PDE4D-4 with IC50 values in the range of 1.34–7.26 μM (Table 1) [42]. This 
activity potential is comparable with the positive control rolipram, a standard PDE4 in-
hibitor (IC50 0.62 μM). Since a small difference has been reported in the activity level of all 
these compounds, it may lead to the conclusion that the diformylphloroglucinol moiety is 
required for PDE4D2 inhibitory activity. The genus Psidium produced a diverse range of 
meroterpenoids bearing phloroglucinol-coupled to sesquiterpenoids or monoterpenes. As 
illustrative of this variety, consider phloroglucinol-coupled to the cubebane sesquiterpe-
noid core to produce compounds 44 and 45, and compound 46 has globulane as the ter-
pene unit while 49 has caryolane and 50 has caryophyllane, whereas compounds 51–53 
have cadinane as the terpene unit [42].  
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Figure 7. Structures of phloroglucinol-based meroterpenoids 44–54. 
Phytomeroterpenoid eucalrobusones J–P (55–61) and compound 62 (Figure 8) were 
isolated from Eucalyptus robusta and evaluated for their antifungal activity against C. albi-
cans and C. glabrata [43]. Structural diversity among the meroterpenoids 55–62 is gener-
ated through the wide range of coupling patterns between the sesquiterpenoid and 
phloroglucinol units. Meroterpene 55 bearing an unusual carbon skeleton, viz., the 1-ox-
aspiro[5.6]dodecane unit is formed via the aromadendrane core C-14 rather than C-4. On 
the other hand, metabolite 56 is a guaiane based meroterpene and interestingly, this com-
pound has two oxo bridges between C-10/C-11 and C-3′/C-6 which generates the most 
unusual polycyclic ring system [43]. Moreover, meroterpenes 57–59 are rare aristolane-
based meroterpenoids with only a few examples being reported to date [44]. These me-
tabolites showed different microbial inhibitory potentials (Table 1). Compounds 60 and 
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62 were moderately active against C. albicans with MIC values of 12.54 and 12.50 µg/mL 
respectively, while other members exhibit MIC values of more than 50 µg/mL. Com-
pounds 55, 60 and 62 potentially inhibited the growth of C. glabrata with MIC values de-
termined as 2.57, 1.95, and 2.49 µg/mL, respectively (Table 1) [43] and these activates are 
closer to the standard drugs fluconazole (MIC = 0.25 µg/mL) and amphotericin B (MIC = 
0.26 µg/mL). 
 
Figure 8. Structures of phloroglucinol-based meroterpenoids 55–62. 
Eucalyptus robusta produces eucarobustols A–I (63–71) (Figure 9), which have been 
identified as PTP1B inhibitors, since all these isolates displayed significant inhibitory po-
tential (IC50 = 1.3–5.6 μM, Table 1). In this assay, the standard compound oleanolic acid 
inhibited the enzyme activity with an IC50 value of 2.34 μM [44]. The published results 
(Table 1) revealed that compounds 63 (IC50: 1.3 μM), 67 (IC50: 1.8 μM), and 85 (IC50: 1.6 μM) 
were even more potent than oleanolic acid. It is speculated from the cases of the two pairs 
of epimers (63/64 and 69/70) that the relative configuration of H-9′ can play a central role 
in the activity and that this provides useful information for further investigations into a 
structure-activity relationship [44]. Metabolite 65 displays an unusual coupling moiety of 
acylphloroglucinol and guaiane through the C-4–C-7′ bond. Compound 63 has an 
acylphloroglucinol coupled sesquiterpene viz., aristolane-type while compounds 67–71 
have aromadendrane type sesquiterpene linked to acylphloroglucinol units. Guavadial 
(72), isolated from Psidium guajava L. has caryophyllene attached to a diformyl phloroglu-
cinol core [45]. Eucalyptusdimers A–C (73–75) were reported from Eucalyptus robusta and 
were identified via intensive spectroscopic methods. These compounds were shown to 
bear a fused skeleton between two acylphloroglucinol and two phellandrene cores. Fur-
thermore only compound 73 illustrated anti-AChE effects with an IC50: 17.71 μM [46]. 
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Figure 9. Structures of phloroglucinol-based meroterpenoids 63–75. 
Meroterpenoids, callisalignenes A–C (76–78) (Figure 10) were produced by Calliste-
mon salignus and these compounds were not active in antimicrobial screening [47]. Mero-
terpenoids, drychampones A–C (79–81), were produced by Dryopteris championii. Moreo-
ver compounds 80 and 81 featuring an 11/6/6 core coupled with a pyronone moiety [48]. 
Guajavadimer A (82) was produced by Psidium guajava and illustrated moderate hepato-
protective effects. Moreover guajavadimer A (82) featured unusual dimeric meroterpe-
noids bearing two caryophyllene skeletons coupled with a benzylphloroglucinol along 
with flavonone unit [49]. 
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Figure 10. Structures of phloroglucinol-based meroterpenoids 76–82. 
(±)-Dryocrassoids E–J [(±)-83–88], (Figure 11) were reported from Dryopteris crassirhi-
zoma and these metabolites illustrated moderate anti-HSV-1, and anti-RSV effects [50]. 
Psiguadiols A–J (89–98) were produce by Psidium guajava and evaluated for PTP1B inhi-
bition. Moreover, compounds 83 (IC50: 4.7 μM), 95 (IC50: 6.2 μM), and 96 (IC50: 9.2 μM) 
demonstrated significant PTP1B inhibition while meroterpenes 90–92 illustrated good in-
hibition with IC50 of 11.0, 11.9, and 10.7 μM, respectively. On the other hand the remaining 
compounds possess PTP1B inhibition with IC50 of <23.0 while all compounds were more 
potent than standard oleanolic acid (IC50: 40.7 μM) [51]. 
Biomolecules 2021, 11, 957 12 of 56 
 
 
Figure 11. Structures of phloroglucinol-based meroterpenoids 83–98. 
Littordials A–E (99–103), (Figure 12) phloroglucinol-β-caryophyllene coupled mero-
terpenoids were produce by Psidium littorale. Moreover, meroterpenes 100, 101 and 103 
illustrated cytotoxic effects towards B16 and MDA-MB-231 with IC50: ranging from 6.6 to 
9.2 μM [52]. Meroterpenes, eucalrobusone Q–Z (104–115) were isolated from Eucalyptus 
robusta and these metabolites have terpene moieties such as cadinane, aromadendrane, 
cubebane, pinane and aromatic menthane. (+)-Eucalrobusone X (113) illustrated the most 
significant antifungal effects towards Candida albicans (MIC50: 10.7 μg/mL) while eucalro-
busone U (109) demonstrated the highest anti-C. glabrata effects with MIC50: 1.53 μg/mL 
[53]. 
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Figure 12. Structures of phloroglucinol-based meroterpenoids 99–115. 
Melaleucadines A (116) and B (117), (Figure 13) phloroglucinol-terpene meroterpe-
noid metabolites have the phloroglucinol unit coupled with β-pinene to form the hu-
mulene-type sesquiterpenes respectively. Moreover, meroterpenes 116 and 117 illustrated 
a significant neuroprotective effect with cell viability of 53.7% and 58.3%, respectively [54]. 
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Littordial F (118) was isolated from Psidium littorale which has an unusual 6/8/9/4-tetracy-
clic core. This compound exhibited moderate cytotoxic effects on B16, MDA-MB-321, and 
A549 cells with IC50 ranging from 21.5 to 41.5 µM [55]. Phloroglucinol based meroterpenes 
named fischernolides A–D (119–122), having a diterpene core (Figure 13), were produced 
by Euphorbia fischeriana. Meroterpenes 120 and 122 illustrated significant cytotoxic effects 
towards HT-29, Bel-7402, MCF-7, A549, and HeLa with IC50 values from 2.0 to 8.6 μM [56]. 
Euphoractone (123) was isolated from Euphorbia fischeriana and displayed cytotoxic effects 
towards H23 and H460 cells with the IC50: 21.0 and 20.9 mmol/L respectively [57]. 
 
Figure 13. Structures of phloroglucinol-based meroterpenoids 116–123. 
Table 1. Phloroglucinol-Derived Metroterpenoids and their biological effects. 
Compounds Source Activities Ref. 
Psiguajavadial A (1) Psidium guajava 
Cytotoxic effects: HCT116 = IC50 7.60 µM; CCRF-CEM = IC50 25.2 µM; 
DU145 = IC50 20.2 µM; Huh7 = IC50 48.8 µM; A549 = IC50 2.99 µM 
[33,34] 
Psiguajavadial B (2) Psidium guajava 
Cytotoxic effects: HCT116 = IC50 21.6 µM; CCRF-CEM = IC50 9.63 µM; 
DU145 = IC50 26.3 µM; Huh7 = IC50 13.7 µM; A549 = IC50 0.90 µM 
[33,34] 
Guadial A (3) Psidium guajava 
Cytotoxic effects: HCT116 = IC50 5.74 µM; CCRF-CEM = IC50 2.95 µM; 
DU145 = IC50 5.35 µM; Huh7 = IC50 28.0 µM; A549 = IC50 9.62 µM; En-
zyme Inhibition: PDE4D-4 = IC50 2.70 μM 
[33,34] 
Guajavadial A (4) Psidium guajava 
Cytotoxic effects: HL-60 = IC50 4.73 µM; A-549 = IC50 5.62 µM; SMMC-
7721 = IC50 4.37 µM; MCF-7 = IC50 22.28 µM; SW480 = IC50 14.55 µM; En-
zyme Inhibition: PDE4D-4 = IC50 2.01 μM 
[35] 
Guajavadial B (5) Psidium guajava 
Cytotoxic effects: HL-60 = IC50 6.49 µM; A-549 = IC50 5.78 µM; SMMC-
7721 = IC50 5.05 µM; MCF-7 = IC50 18.02 µM; SW480 = IC50 13.07 µM 
35] 
Guajavadial C (6) Psidium guajava 
Cytotoxic effects: HL-60 = IC50 3.38 µM; A-549 = IC50 5.66 µM; SMMC-
7721 = IC50 3.54 µM; MCF-7 = IC50 14.54 µM; SW480 = IC50 18.97 µM 
[35] 
Eucalrobusone A (7) Eucalyptus robusta Cytotoxic effects: HepG2 = IC50 18.52 µM; U2OS = IC50 45.00 μM [36] 
Eucalrobusone C (9) Eucalyptus robusta 
Cytotoxic effects: HepG2 = IC50 7.40 µM; U2OS = IC50 8.99 μM; MCF-7 = 
IC50 8.50 μM 
[36] 
Eucalrobusone D (10) Eucalyptus robusta Cytotoxic effects: HepG2 = IC50 26.78 μM [36] 
Eucalrobusone H (14) Eucalyptus robusta Cytotoxic effects: U2OS = IC50 42.25 μM [36] 
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Eugenial B (17) Eugenia umbelliflora 
Cytotoxic effects: K562 = IC50 42.8 μM; Nalm-6 = IC50 70.5 μM; B16F10 = 
IC50 12.0 μM 
[37] 
Eugenial C (18) Eugenia umbelliflora 
Cytotoxic effects: K562 = IC50 0.38 μM; Nalm-6 = IC50 10.5 μM; B16F10 = 
IC50 6.0 μM 
[37] 
Eugenial D (19) Eugenia umbelliflora 
Cytotoxic effects: K562 = IC50 1.90 μM; Nalm-6 = IC50 7.75 μM; B16F10 = 
IC50 3.20 μM 
[37] 
Eugenial E (20) Eugenia umbelliflora 
Cytotoxic effects: K562 = IC50 4.97 μM; Nalm-6 = IC50 29.1 μM; B16F10 = 
IC50 8.80 μM 
[37] 
Eucalteretials C (23) Eugenia tereticornis Cytotoxic effects: HCT116 = IC50 4.8 μM [37] 
Eucalypglobulusal F (31) Eugenia globulus Cytotoxic effects: CCRF-CEM = IC50 3.3 μM [37] 
(+)-Japonicol B (37a) Hypericum japonicum Antiviral effects: KSHV = EC50 8.75 μM [40] 
(+)-Japonicol E (40a) Hypericum japonicum Antiviral effects: KSHV = IC50: 8.30 μM [41] 
(−)-Japonicol E (40b) Hypericum japonicum Antiviral effects: KSHV = IC50: 24.4 μM [41] 
(+)-Japonicol G (42a) Hypericum japonicum Antiviral effects: KSHV = IC50: 21.3 μM [41] 
(−)-Japonicol G (42b) Hypericum japonicum Antiviral effects: KSHV = IC50: 6.7 μM [41] 
(+)-Japonicol H (43a) Hypericum japonicum Antiviral effects: KSHV = IC50: 4.90 μM [41] 
(−)-Japonicol H (43b) Hypericum japonicum Antiviral effects: KSHV = IC50: 29.4 μM [41] 
Psiguajadial A (44) Psidium guajava Enzyme Inhibition: PDE4D-4 = IC50 3.11 μM [42] 
Psiguajadial B (45) Psidium guajava Enzyme Inhibition: PDE4D-4 = IC50 5.03 μM [42] 
Psiguajadial C (46) Psidium guajava Enzyme Inhibition: PDE4D-4 = IC50 4.50 μM [42] 
Psiguajadial D (47) Psidium guajava Enzyme Inhibition: PDE4D-4 = IC50 4.14 μM [42] 
Psiguajadial E (48) Psidium guajava Enzyme Inhibition: PDE4D-4 = IC50 3.25 μM [42] 
Psiguajadial F (49) Psidium guajava Enzyme Inhibition: PDE4D-4 = IC50 2.63 μM [42] 
Psiguajadial G (50) Psidium guajava Enzyme Inhibition: PDE4D-4 = IC50 1.34 μM [42] 
Psiguajadial H (51) Psidium guajava Enzyme Inhibition: PDE4D-4 = IC50 1.81 μM [42] 
Psiguajadial I (52) Psidium guajava Enzyme Inhibition: PDE4D-4 = IC50 2.51 μM [42] 
Psiguajadial J (53) Psidium guajava Enzyme Inhibition: PDE4D-4 = IC50 2.53 μM [42] 
Psiguajadial K (54) Psidium guajava Enzyme Inhibition: PDE4D-4 = IC50 3.68 μM [42] 
Psiguadial A (55) Psidium guajava Enzyme Inhibition: PDE4D-4 = IC50 7.26 μM [42] 
Guapsidial A (56) Psidium guajava Enzyme Inhibition: PDE4D-4 = IC50 5.61 μM [42] 
Psiguajadial L (57) Psidium guajava Enzyme Inhibition: PDE4D-4 = IC50 1.37 μM [42] 
Eucarobustol A (63) Eucalyptus robusta Enzyme Inhibition: PTP1B = IC50 1.3 μM [44] 
Eucarobustol B (64) Eucalyptus robusta Enzyme Inhibition: PTP1B = IC50 4.3 μM [44] 
Eucarobustol C (65) Eucalyptus robusta Enzyme Inhibition: PTP1B = IC50 4.3 μM [44] 
Eucarobustol D (66) Eucalyptus robusta Enzyme Inhibition: PTP1B = IC50 2.9 μM [44] 
Eucarobustol E (67) Eucalyptus robusta Enzyme Inhibition: PTP1B = IC50 4.1 μM [44] 
Eucarobustol F (68) Eucalyptus robusta Enzyme Inhibition: PTP1B = IC50 5.6 μM [44] 
Eucarobustol G (69) Eucalyptus robusta Enzyme Inhibition: PTP1B = IC50 1.8 μM [44] 
Eucarobustol H (70) Eucalyptus robusta Enzyme Inhibition: PTP1B = IC50 3.0 μM [44] 
Eucarobustol I (71) Eucalyptus robusta Enzyme Inhibition: PTP1B = IC50 1.6 μM [44] 
Eucalyptusdimers A (73) Eucalyptus robusta Enzyme Inhibition: AChE = IC50 17.71 μM [44] 
4. Syncarpic Acid/β-Triketones-Based Meroterpenes 
Baeckea frutescens has been reported to produce a small library of polymethylated 
phloroglucinol meroterpenoids, viz., baeckfrutones A–L (124–135) (Figure 14). The struc-
tures of these metabolites were also elucidated via spectroscopic methods, X-ray diffrac-
tion techniques, and ECD calculations [58]. Meroterpenoids 124 and 125–127 are novel 
hybrid compounds of the enone-type phloroglucinols linked with phellandrene and sab-
inene, respectively. Biogenetically, meroterpenoids 124–135 involve regio- and stereose-
lective [4 + 2] cycloaddition reactions between demethylated tasmanone or tasmanone and 
monoterpenoids, viz., sabinene, β-phellandrene, and β-piene. Enone-type phloroglucinol 
(-)-125 (IC50: 1.33 μM) and 133 (IC50: 4.04 μM) showed potent inhibition of DU145 cell lines, 
which is more potent than VP-16, the standard inhibitor (IC50 = 5.22 μM). On the other 
hand, compounds 129 and 134 displayed moderate growth inhibition of A549 (IC50: 15.6 
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μM) and HCT116 (IC50: 12.8 μM) cell lines (Table 2). Moreover compounds 129 (74.4%), 
130 (75.3%), (+)-132 (55.1%), and 131 (75%) illustrated significant anti-inflammatory ef-
fects. Additionally, compound 133 (IC50: 43.0 μM) displayed good effects towards AChE. 
The remainder of the metabolites were either weakly active or inactive [58]. 
 
Figure 14. Structures of syncarpic acid/β-triketones-based meroterpenes 124–135. 
Further phloroglucinol-derived phytomeroterpenoids, named baeckfrutones M–S 
(136–142) (Figure 15), were isolated from B. frutescens. Biogenetically, meroterpenoids 
136–142 also involve a [4 + 2] cycloaddition condensation between demethylated tas-
manone or tasmanone and monoterpenoids viz., sabinene, thujene, and caryophyllene 
[59]. Compounds 136–142 were tested for anti-inflammatory activity, in which it was 
found that only (+)-136 (IC50: 20.8 μM) and 142 (IC50: 36.2 μM) displayed potent effects and 
their activities were more potent than the positive control L-NG-monomethyl arginine (L-
NMMA, IC50 = 54.0 μM). Moreover, none of these compounds were active towards HL-
60, A-549, MCF-7, SW480, and SMMC-7721 cancer cells [59]. 
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Figure 15. Structures of syncarpic acid/β-triketones-based meroterpenes 136–142. 
Hyperjaponol H (143) (Figure 16), obtained from Hypericum japonicum, was identified 
with the help of spectroscopic analyses and a comparison of the Cotton effects of an ECD 
spectrum. Hyperjaponol H (143) is a hybrid of tasmanone and the monoterpene germa-
crane. An assay on lytic DNA replication of EBV in B95-8 cells indicated that this com-
pound displayed moderate inhibitory effects with an EC50 value of 25.00 μM [60] (Table 
2). Spectroscopic identification of the secondary metabolites of Rhodomyrtus tomentosa re-
vealed that tomentosenol A (144), 4S-focifolidione (145) and 4R-focifolidione (146) contain 
a unique free syncarpic acid-derived meroterpenoid skeleton. Compound 144 was also 
confirmed through biomimetic synthesis and was shown to potentially inhibit the growth 
of S. aureus with an MIC value of 4.74 μM, which has been reported to be comparable with 
the standard drug vancomycin (MIC = 1.23 μM). Since the other compounds 113 and 146 
have been reported as being inactive, it seems that the pyran ring is responsible for reduc-
ing the antibacterial activity. In addition, tomentosenol A (144) moderately inhibited the 
growth of MCF-7 (IC50 = 8.66 μM), NCI-H460 (IC50 = 8.62 μM), SF-268 (IC50 = 10.01 μM) 
and HepG-2 (IC50 = 9.44 μM) (Table 2) [61]. 
 
Figure 16. Structures of syncarpic acid/β-triketones-based meroterpenes 143–146. 
Liu et al. [62] isolated syncarpic acid-derived meroterpenoids from Myrtus communis. 
Spectroscopic analysis revealed that myrtucommulones (147–149) (Figure 17) and ()-150 
having a different skeleton to compound 147 affords a unique octahydrospiro{bicy-
clo[7.2.0]undecane-2,2′-chromene} tetracyclic ring system. Compounds 147–149 bear a 
syncarpic acid coupled with the sesquiterpene viz., caryophyllene while compound 150 
has humulene as the sesquiterpene core [54]. In an MTT assay, compound 147 inhibited 
the growth of HepG2 (IC50: 4.3 μM) and MDA-MB-231 cells (IC50: 19.9 μM), whereas me-
tabolite 150 demonstrated IC50 values of 40.7 and 40.0 μM, respectively (Table 2). Com-
pounds 149 and 150 were inactive under these conditions [28]. In 2012, Cottiglia et al. [63] 
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reported myrtucommulone K (149a) from M. communis and based on NMR data, the au-
thors confirmed that the structure of 149 is identical to myrtucommulone K (149a). 
 
Figure 17. Structures of syncarpic acid/β-triketones-based meroterpenes 147–157. 
Frutescone A–G [(151–156), (+)-157 and (−)-157] were obtained from Baeckea frutescens 
L. and were shown to possess chemical structures similar to compounds 147–149. Com-
pounds 151–156 bear a triketone coupled with the sesquiterpene, viz., caryophyllene 
while compound 150 has humulene as the sesquiterpene core (Figure 17) [64]. Com-
pounds 151 and 154 displayed anticancer activity against Caco-2 with IC50 values of 8.08 
µM and 10.20 µM, respectively, whereas, compound 155 inhibited the growth of Caco-2 
and A549 cell lines with IC50 values of 7.96 µM. The other metabolites were only weakly 
active (Table 2), but all were inactive against HepG2 cells [64]. 
Triketone-caryophyllene-based meroterpenoids isolated from Rhodomyrtus tomentosa 
were identified as rhodomyrtials A and B (158 and 159), rhodomentone A (160) and to-
mentodiones A-D (161–164) (Figure 18) and all were evaluated for their inhibitory poten-
tial on tumor metastasis. Compound 161 has a unique 1-oxaspiro[5,8]tridecane core bear-
ing two units of triketone. Biological evaluation demonstrated that only compound 164 
displayed significant metastatic effects towards DLD-1 cells. Since no study has been car-
ried out on the mode of action, it should be mentioned that the stereochemistry at C-7 
could play an important role in the activity [65]. 
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Figure 18. Structures of syncarpic acid/β-triketones-based meroterpenes 158–173. 
Zhang et al. [66] separated the tomentodiones E–M (165–173) (Figure 18) from an 
extract of Rhodomyrtus tomentosa. It was hypothesized that compounds 165–173 could 
form via a Diels–Alder reaction between triketone and three appropriate terpenes viz., β-
calacorene, (+)-sabinene, and myrcene [66]. Since compounds 165, ()-168, ()-169 and 
170–173 were non-cytotoxic towards doxorubicin-resistant human breast carcinoma cells 
(MCF-7/DOX), and compound (+)-168 exhibited a significant potentiation effect by 16.5 
reversal fold for MCF-7/DOX, activity was also observed for (+)-169 (10.1 fold), (−)-169 (7.4 
fold), 173 (5.6 fold), (−)-168 (4.7 fold), and 169 (4.5 fold). Comparison of the activity and 
structural features of these compounds, suggests that the stereochemistry at C-7′ might be 
significant in determining and enhancing biological effects [66]. 
Callisalignenes G–I (174–176) (Figure 19), isolated from the medicinal plant Calliste-
mon salignus, illustrate β-triketone and monoterpene moieties in their structures. Spectro-
scopic analysis and CD calculations revealed that compounds 175 and 176 also possess a 
sec-butyl moiety at C-7, which is not so common in natural products. The three metabolites 
inhibited the growth of HCT116 cancer cell lines with IC50 values of 8.51, 9.12 and 16.33 
μM, respectively (Table 2). This activity has been reported to be even better than the pos-
itive control (VP-16, 20.26 µM). Compounds 174 and 176 also exhibited cytotoxicity 
against A549 cell lines with IC50 values of 12.85 and 10.03 μM, respectively, which is also 
better than VP-16 (IC50 = 25.79 ± 6.2 µM), respectively [67]. 
 
Figure 19. Structures of syncarpic acid/β-triketones-based meroterpenes 174–176. 
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The small library of compounds 177–187 (Figure 20) were separated from Baeckea fru-
tescens and identified through spectroscopic analyses, ECD calculations and X-ray crystal-
lography. Metabolites 177–187 could form between the common triketone (tasmanone) 
sesquiterpenes/monoterpenes viz., bicyclosequiphellandrene (compounds 145–147), β-
caryophyllene (compound 148), β-cubebene (compounds 181 and 182), (−)-sabinene (com-
pounds 183 and 184), β-pinene (compound 185), and myrcene (compounds 186 and 187) 
[68]. 
 
Figure 20. Structures of syncarpic acid/β-triketones-based meroterpenes 177–187. 
Among other antioxidant meroterpenoids, frutescones H–R (177–182) only moder-
ately inhibited the NO production in LPS-induced RAW 264.7 cells with IC50 values in the 
range of 15.17–50.0 μM (Table 2), whereas, compounds 183–187 exhibited significant IC50 
values (0.36–6.50 μM) [68]. These compounds are more potent inhibitors of NO produc-
tion than the standard N-monomethyl-L-arginine (L-NMMA, IC50 = 30.92 μM). Since com-
pound 184 showed the highest anti-inflammatory potential (IC50 = 0.36 μM), it was further 
evaluated against LPS-induced upregulation of TNF-α and IL-6. A review of the activity 
level and structural features of compounds 177–187 revealed that the overall structure of 
ring A plays a more important role in the potential of these compounds, especially the 
position of the double bonds and keto groups [68]. 
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Baefrutones A–F (188–193) (Figure 21) bearing a rather rare triketone-phloroglucinol 
unit coupled to sesquiterpene/monoterpene skeletons were isolated from Baeckea fru-
tescens. Interestingly, in compounds 188–191, the triketone-phloroglucinol core was at-
tached to α-thujene while meroterpenoids 192 and 193 have a β-caryophyllene framework 
instead of the α-thujene. Moreover compounds 188–191 displayed anti-inflammatory ef-
fects towards NO production with IC50 = 9.1 to 18.0 μM (Table 2), while meroterpenoids 
192 and 193 were not active. Notably compounds 188–191 were more potent than the pos-
itive control L-NMMA (IC50 = 30.9 μM) [69]. 
 
Figure 21. Structures of syncarpic acid/β-triketones-based meroterpenes 188–193. 
Filicinic acid-based meroterpenoids, the hyperjaponols A–G (194–200) (Figure 22) 
were isolated from Hypericum japonicum and comprise 6/6/7/5, 6/6/11, or 6/6/10 sized ring 
frameworks. Moreover compounds 194–196 were reported as enantiomeric pairs and 
these compounds displayed weak to moderate anti-EBV effects while compound 200 was 
not active. Enantiomer 194a displayed an EC50 value of 10.33 μM, while its enantiomer 
195b was weakly active (Table 2). In a similar enantiomeric differentiation, metabolite 
195a (EC50 = 0.57 μM) was more active than 163b (EC50 = 6.60 μM) (Table 2). Among other 
isolates, compound 197 exhibited the lowest EC50 value of 0.49 μM, which is 5-fold lower 
than the standard drug ganciclovir (EC50 2.86 μM) [70]. 
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Figure 22. Structures of syncarpic acid/β-triketones-based meroterpenes 194–200. 
Meroterpenoids, callisalignenes D–F (201–203) (Figure 23) were produced by Callist-
emon salignus [47] and based on MIC values [71] these compounds were not active in an-
timicrobial screening. In another report, meroterpenoids, myrtucomvalones A–C (204–
206) were reported from Myrtus communis and compound 206 illustrated moderate anti-
viral effects towards the respiratory syncytial virus (RSV) with IC50: 15.8 µM [72]. Liu et 
al. [73] reported two meroterpenoids, rhodomentones A (207) and B (208) were produced 
by Rhodomyrtus tomentosa and featured an uncommon caryophyllene-conjugated oxa-
spiro[5.8]tetradecadiene core. In addition, Senadeera et al. [74] reported intermediones A–
D (209–212) from the tree Corymbia intermedia. Compounds 209, 210, and 212 possessed 
moderate antiplasmodial effects towards Plasmodium falciparum with IC50: 12.5, 9.9 to 20.8 
μM, respectively. 
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Figure 23. Structures of syncarpic acid/β-triketones-based meroterpenes 201–212. 
Elodeoidols A–I (213–221) (Figure 24) were isolated from Hypericum elodeoides. Com-
pounds 217, 220 and 221 illustrated moderate antibacterial effects towards Streptococcus 
mutans, Fusobacterium nucleatum, and Streptococcus sanguis. In addition, compounds 215, 
219 and 220 demonstrated potent NO inhibitory effects towards LPS induced RAW264.7 
cells with IC50 ranging from 10 to 34 μM [75]. Moreover, rhotomentodiones C–E, (222–224) 
(Figure 24) were produced by Rhodomyrtus tomentosa. Rhotomentodione D (223) demon-
strated antibacterial effects towards Propionibacterium acnes (MIC: 12.5 μg/mL) and AChE 
inhibitory effects with an IC50: 22.9 μM [76]. Frutescones S–U (225–227) were isolated from 
Baeckea frutescens and meroterpene 225 demonstrated potent anti-inflammatory effects 
with an IC50: 0.81 μmol/L [77]. 
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Figure 24. Structures of syncarpic acid/β-triketones-based meroterpenes 213–227. 
β-Triketone-based meroterpenes rtomentones A–H (228–235) (Figure 25) were iso-
lated from Rhodomyrtus tomentosa and all compounds were not active towards A549, 
MDA-MB-231, and DLD-1 cancer cells [78]. (±)-Dryocrassoids A–D (236–239) were re-
ported from Dryopteris crassirhizoma. Moreover these compounds exhibited moderate anti-
HSV-1 activity with IC50: ranging from 23.4 to 95.0 µM. In addition, compounds 236–239 
also possessed anti-RSV effects with IC50: ranging from 11.4 to 50.2 µM. [50]. 
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Figure 25. Structures of syncarpic acid/β-triketones-based meroterpenes 228–239. 
Table 2. Syncarpic acid/β-triketones-based meroterpenes. 
Compounds Source Anticancer Ref. 
(−)-Baeckfrutone B (125) Baeckea frutescens Cytotoxic effects: DU145 = IC50 79.45 μM [58] 
(+)-Baeckfrutone C (126) Baeckea frutescens 
Cytotoxic effects: HCT116 = IC50 62.64 μM; Hela = IC50 85.79 μM; DU145 
= IC50 17.65 μM; A549 = IC50 86.68 μM 
[58] 
(−)-Baeckfrutone C (126) Baeckea frutescens 
Cytotoxic effects: HCT116 = IC50 49.09 μM; Hela = IC50 91.22 μM; DU145 
= IC50 15.85 μM; A549 = IC50 86.62 μM 
[58] 
Baeckfrutone D (127) Baeckea frutescens 
Cytotoxic effects: HCT116 = IC50 38.32 μM; Hela = IC50 83.85 μM; DU145 
= IC50 6.46 μM; A549 = IC50 76.47 μM 
[58] 
Baeckfrutone F (129) Baeckea frutescens 
Cytotoxic effects: HCT116 = IC50 39.5 μM; DU145 = IC50 80.72 μM; A549 
= IC50 15.61 μM; Anti-inflammatory effects: 74.4% 
[58] 
Baeckfrutone G (130) Baeckea frutescens 
Cytotoxic effects: HCT116 = IC50 49.76 μM; Hela = IC50 31.87 μM; DU145 
= IC50 17.40 μM; A549 = IC50 62.64 μM; Anti-inflammatory effects: 75.3% 
[58] 
Baeckfrutone H (131) Baeckea frutescens 
Cytotoxic effects: HCT116 = IC50 19.50 μM; Hela = IC50 30.44 μM; DU145 
= IC50 25.14 μM; A549 = IC50 82.75 μM; Anti-inflammatory effects: 55.1% 
[58] 
Baeckfrutone I (132) Baeckea frutescens 
Cytotoxic effects: HCT116 = IC50 19.50 μM; Hela = IC50 53.71 μM; DU145 
= IC50 26.11 μM; A549 = IC50 84.13 μM; Anti-inflammatory effects: 75% 
[58] 
Baeckfrutone J (133) Baeckea frutescens 
Cytotoxic effects: HCT116 = IC50 52.93 μM; DU145 = IC50 4.04 μM; A549 
= IC50 79.45 μM 
[58] 
Baeckfrutone K (134) Baeckea frutescens 
Cytotoxic effects: HCT116 = IC50 12.89 μM; DU145 = IC50 77.06 μM; A549 
= IC50 80.11 μM 
[58] 
Baeckfrutone L (135) Baeckea frutescens 
Cytotoxic effects: HCT116 = IC50 16.48 μM; Hela = IC50 19.81 μM; DU145 
= IC50 10.0 μM; A549 = IC50 88.81 μM 
[58] 
Hyperjaponol H (143) Hypericum japonicum Antiviral effects: EBV = EC50 25.0 μM [61] 
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Tomentosenol A (144) Rhodomyrtus tomentosa 
Cytotoxic effects: MCF-7 = IC50 8.66 μM; NCI-H460 = IC50 8.62 μM; SF-
268 = IC50 10.01 μM; HepG-2 = IC50 9.44 μM 
[61] 
Myrtucommulone (147) Myrtus communis Cytotoxic effects: HepG2 = IC50 4.39 μM; MDA-MB-231 = IC50 19.92 μM [62] 
Myrtucommulone (148) Myrtus communis Cytotoxic effects: HepG2 = IC50 40.7 μM; MDA-MB-231 = IC50 40.0 μM [62] 
Frutescone A (151) Baeckea frutescens Cytotoxic effects: Caco-2 = IC50 8.08; A549 = IC50 20.07 µM [64] 
Frutescone B (152) Baeckea frutescens Cytotoxic effects: Caco-2 = IC50 23.25 µM; A549 = IC50 41.33 µM [64] 
Frutescone C (153) Baeckea frutescens Cytotoxic effects: Caco-2 = IC50 14.83 µM; A549 = IC50 27.74 µM [64] 
Frutescone D (154) Baeckea frutescens Cytotoxic effects: Caco-2 = IC50 10.20 µM; A549 = IC50 26.25 µM [64] 
Frutescone E (155) Baeckea frutescens Cytotoxic effects: Caco-2 = IC50 7.96 µM; A549 = IC50 5.55 µM [64] 
Frutescone F (156) Baeckea frutescens Cytotoxic effects: Caco-2 = IC50 16.51 µM; A549 = IC50 39.02 µM [64] 
(±)-Frutescone G (157) Baeckea frutescens Cytotoxic effects: Caco-2 = IC50 14.31 µM; A549 = IC50 25.71 µM [64] 
Callisalignene G (174) Callistemon salignus Cytotoxic effects: HCT116 = IC50 8.51 μM; A549 = IC50 12.85 μM [67] 
Callisalignene H (175) Callistemon salignus Cytotoxic effects: HCT116 = IC50 9.12 μM [67] 
Callisalignene I (176) Callistemon salignus Cytotoxic effects: HCT116 = IC50 16.33 μM; A549 = IC50 10.03 μM [67] 
Frutescone I (178) Baeckea frutescens Anti-inflammatory effects: NO production = IC50 18.75 μM [68] 
Frutescone L (179) Baeckea frutescens Anti-inflammatory effects: NO production = IC50 30.54 μM [68] 
Frutescone M (180) Baeckea frutescens Anti-inflammatory effects: NO production = IC50 15.17 μM [68] 
()-Compound (181) Baeckea frutescens Anti-inflammatory effects: NO production = IC50 1.80 μM [68] 
Compound (182) Baeckea frutescens Anti-inflammatory effects: NO production = IC50 0.36 μM [68] 
Compound (183) Baeckea frutescens Anti-inflammatory effects: NO production = IC50 3.70 μM [68] 
()-Compound (184) Baeckea frutescens Anti-inflammatory effects: NO production = IC50 2.07 μM [68] 
()-Compound (185) Baeckea frutescens Anti-inflammatory effects: NO production = IC50 6.50 μM [68] 
Baefrutone A (188) Baeckea frutescens Anti-inflammatory effects: NO Production = IC50 9.15 μM [69] 
Baefrutone B (189) Baeckea frutescens Anti-inflammatory effects: NO Production = IC50 17.73 μM [69] 
Baefrutone C (190) Baeckea frutescens Anti-inflammatory effects: NO Production = IC50 11.62 μM [69] 
Baefrutone D (191) Baeckea frutescens Anti-inflammatory effects: NO Production = IC50 18.04 μM [69] 
hyperjaponols A (194a) Hypericum japonicum Antiviral effects: EBV = EC50 10.33 μM [70] 
Hyperjaponol B (195a) Hypericum japonicum Antiviral effects: EBV = EC50 0.57 μM [70] 
Hyperjaponol B (195b) Hypericum japonicum Antiviral effects: EBV = EC50 6.60 μM [70] 
Hyperjaponol D (197) Hypericum japonicum Antiviral effects: EBV = EC50 0.49 μM [70] 
5. Alklaoid-Based Meroterpenoids 
Phenazine- and Phyridine-Based Meroterpenoids 
Phenazine-derived meroterpenoids, viz., marinocyanins A–F (240–245) (Figure 26) 
along with lavanducyanin (246) were produced by the marine Actinomycete strains. Com-
pounds 240–245 are unique secondary metabolites comprising the bromo-phenazinone 
nucleus supplemented by N-isoprenoid moieties or a cyclolavandulyl ring in their struc-
tures [79]. Lavanducyanin (246) was re-isolated from Streptomyces sp. as a testosterone 5α-
reductase inhibitor and was named WS-9659A Quite recently Kohatsu et al. [80] reported 
the total synthesis of lavanducyanin (246). Marinocyanin A (240) has been reported to be 
a potent antibiotic, since it potentially inhibited (MIC = 0.95 μM) the growth of amphoter-
icin-resistant Candida albicans in vitro, while the other test compounds were reported as 
only weak inhibitors (Table 3). In addition, marinocyanins A (240) and B (241) illustrated 
significant in vitro cytotoxic effects towards human colon carcinoma (HCT-116: 240: IC50: 
0.049 μM; 170: IC50: 0.029 μM). SAR studies showed that the cyclic structure of the terpe-
noidal part (cyclolavandulyl ring) plays a significant role in the antifungal activity, and 
that the halogen plays no particular role in the activity [79]. The standard drugs used in 
these assays were vancomycin (MIC = 0.27 µM) for S. aureus and amphotericin B (MIC = 
0.084 µM) for C. albicans. Zhang et al. [81] isolated an unusual C21 pyridine bearing mer-
oterpenoid 247 from the sponge Cacospongia sp. 
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Figure 26. Structures of alkaloid-based meroterpenoids 240–247. 
Table 3. Alkaloids-based meroterpenoids. 
Compounds Source Anticancer Ref. 
Marinocyanin A (240) Actinomycete strains 
Cytotoxic effects: HCT-116 = IC50 0.049 μM; Antimicrobial effects: Candida 
albicans = MIC 0.95 μM; Staphylococcus aureus = MIC 2.3 μM 
[79] 
Marinocyanin B (241) Actinomycete strains 
Cytotoxic effects: HCT-116 = IC50 0.029 μM; Antimicrobial effects: Candida 
albicans = MIC 5.79 μM; Staphylococcus aureus = MIC 33.92 μM 
[79] 
Marinocyanin C (242) Actinomycete strains 
Antimicrobial effects: Candida albicans = MIC 3.90 μM; Staphylococcus aureus 
= MIC 30.71 μM 
[79] 
Marinocyanin D (243) Actinomycete strains 
Antimicrobial effects: Candida albicans = MIC 14.65 μM; Staphylococcus aureus 
= MIC 36.62 μM 
[79] 
Marinocyanin E (244) Actinomycete strains 
Antimicrobial effects: Candida albicans = MIC 14.65 μM; Staphylococcus aureus 
= MIC 36.62 μM 
[79] 
Marinocyanin F (245) Actinomycete strains 
Antimicrobial effects: Candida albicans = MIC 14.65 μM; Staphylococcus aureus 
= MIC 36.62 μM 
[79] 
Lavanducyanin (246) Streptomyces sp. 
Antimicrobial effects: Candida albicans = MIC 114.67 μM; Staphylococcus au-
reus = MIC 56.93 μM 
[79] 
6. Sesquiterpene-Based Meroterpenoids 
The Vietnamian marine sponge Spongia sp. produces a range of meroterpenoids viz., 
langcoquinone A (248) and B (249) (Figure 27). On the other hand, compounds 248 and 
249 were inactive against K. pneumoniae and E. coli, compared to the positive control Kan-
amycin ((MIC = 6.25 and 12.5 µM, respectively) [82]. 
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Figure 27. Structures of sesquiterpene-based meroterpenoids 248–253. 
In another investigation, Nguyen et al. [83] further isolated sesquiterpene-based mer-
oterpenoids, langconols A–C (250–252) (Figure 27) and langcoquinone C (253) from the 
same sponge viz., Spongia sp. Furthermore, compounds 250–252 bear the 4,9-friedodri-
mane skeleton along with phenolic functionality while langcoquinone C (253) has an hy-
droxyquinone instead of the phenolic group. Compound 253 exhibited significant inhibi-
tory activity (MIC = 6.25 µM) against B. subtilis and S. aureus, with the same potential as 
mentioned above for the reference drug ampicillin, whereas, compounds 250 and 253 only 
inhibited the growth of B. subtilis with MICs of 12.5 and 25.0 μM, respectively. Compound 
250 has good potential to be an antibacterial and non-toxic agent and thus offers itself as 
a strong candidate to be studied for the development of a potentially new antibiotic [83]. 
The marine sponge Dysidea sp. produces the sesquiterpene-based meroterpenoids 
dysidphenols A–C (254–256), along with smenospongimine (257), (Figure 28) all of which 
were characterized by spectroscopic analyses and ECD calculations [84]. Moreover com-
pounds 254–256 all comprise a drimane-type sesquiterpene unit attached to a phenolic 
entity through either an oxaspiro center or methylene linkage. On the other hand, com-
pound 267 comprises the 4,9-friedodrimane skeleton attached to hydroxybenzoquinone 
moieties. Compounds 254 and 256 were weakly active against E. coli, B. subtilis and S. 
aureus. However, the other test compounds 257 was found to be more potent against these 
three bacterial species with MIC values between 3.1 and 12.5 µg/mL (Table 4). 
 
Figure 28. Structures of sesquiterpene-based meroterpenoids 254–257. 
The marine sponge Dactylospongia sp. has been reported to produce several mero-
terpenoids including dactylospongins A–D (258–261), melemeleones C–E (262–264), dy-
sidaminone N (265) and 19-O-methylpelorol (266). Compounds 258–265 (Figure 29) have 
a sesquiterpene moiety attached to either a benzothiazole, phenolic, or benzoquinone core 
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through a C-C bond [85]. An interesting feature of meroterpenoids 258 and 259 is that they 
comprise a unique thiazole ring which biogenetically, could be derived from cysteine [86]. 
 
Figure 29. Structures of sesquiterpene-based meroterpenoids 258–266. 
Among other meroterpenoid inhibitors of PTP1B, nakijinol G (267) (Figure 30) inhib-
ited the activity of this enzyme with an IC50 value of 4.8 μM (Table 4). However, the other 
metabolites, nakijinol F (268), hyrtiolacton A (269) all isolated from the same marine 
sponge Hyrtios sp. were inactive. Moreover, none of these compounds were active to-
wards HepG2, RPMI-8226, HeLa, and HL-60 cancer cells. Compounds 267 and 268 have 
a sesquiterpene coupled to a benzoxazole moiety while in compound 269 the benzoxazole 
ring is replaced by an α-pyrone and benzoquinone unit respectively [87]. Another sponge, 
Dysidea villosa also produces some unusual meroterpenoids described as dysivillosins A–
D (270–273), which all inhibited the release of β-hexosaminidase with IC50 ranging from 
8.2 to 19.9 µM (Table 4). In addition, compounds 270–273 exert a positive inhibitory effect 
on LTB-4 and IL-4 and compound 270 potentially inhibited the activation of Syk. It may 
thus be concluded that this meroterpenoid could potentially be a new chemotherapeutic 
scaffold targeting Syk-associated allergies [88]. Dysivillosins A–D (270–273) (Figure 30) 
are meroterpenes bearing a terpene-polyketide-pyridine system and this type of combi-
nation is very rare among meroterpenoids. Moreover, meroterpenoids 270–273 have a 2-
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pyridone core which could be produced biogenetically from L-lysine through amidation, 
decarboxylation, and dehydrogenation reactions [89]. 
 
Figure 30. Structures of sesquiterpene-based meroterpenoids 267–273. 
Chartarolides A–C (274–276) (Figure 31), the secondary metabolites of the sponge 
Niphates recondite, were tested for their cytotoxic properties against HCT-116, BGC-823, 
HepG2, A2780 NCI-H1650, and MCF7 cancer cells. Compound 274 displayed the most 
potent effects with IC50 values ranging from 1.3 to 1.9 μM, followed by compound 275 
(IC50 = 1.6–4.8 μM) (Table 4), while compound 276 has been reported to be the least active 
with IC50 values in the range of 5.4–12.5 μM (Table 4) [90]. However, the activities of these 
metabolites are lower than the reference drug taxol, which displayed IC50 values of 0.001 
to 0.07 against these cell lines. In addition, compounds 274–276 have also been reported 
as inhibitors (IC50 = 2.6–21 μM) of FGFR3, IGF1R and PDGFRb [90], which is lower than 
the activity of the positive control satratoxin H (IC50 = 0.05 µM). Another marine sponge, 
Dysidea arenaria produces dysiarenone (277) and this compound displayed inhibitory ac-
tivities towards COX-2 expression with an IC50 value of 6.4 μM. Compound 277 is a di-
meric C-21 meroterpenoid featuring a unique 2-oxaspiro(bicyclo[3.3.1]nonane-9,1′-cyclo-
pentane) carbon skeleton [91]. This compound reduced the production of PGE2 with IC50: 
6.4 μM and was ~10 times more potent than that of the positive control avarol [91]. 
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Figure 31. Structures of sesquiterpene-based meroterpenoids 274–277. 
Meroterpenoids 278–281 (Figure 32) were produced by the sponge Dysidea sp. [84] 
and their absolute configuration were determined via CD and ECD calculations [92]. In 
another report, Dysidea sp. also produced meroterpenoids, dysiherbols A–C (282–284) fea-
turing a 6/6/5/6-fused core and dysideanone E (285). Moreover, compounds 282–284 illus-
trated potent NF-κB inhibition with IC50 ranging from 0.49–6.4 µM. Notably, compound 
282 was potent towards myeloma cancer (NCI H-929: IC50: 0.58 µM) as well as a potent 
NF-κB inhibitor with IC50 = 0.49 µM) [93]. 
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Figure 32. Structures of sesquiterpene-based meroterpenoids 278–285. 
Cinerols A–K (286–296) (Figure 33) were produced by the sponge Dysidea cinerea 
which was collected from the China Sea. Compounds 286–288 illustrated good PTP1B in-
hibitory effects with IC50 values of 3.8–8.8 μM. On the other hand, only compound 291 
was active towards the SHP-1 enzyme with IC50: of 2.7 μM [94]. Saccharoquinoline (297) 
was isolated from the bacterium Saccharomonospora sp. and featured a drimane-type ses-
quiterpene unit. Saccharoquinoline (286) exhibited good cytotoxicity towards HCT-116 
cancer [95]. Three sesquiterpene based meroterpenes 298–300 were isolated from the 
sponge Dactylospongia elegans and compounds 300 illustrated cytotoxic effects towards 
SW1990, DU145, PANC-1, and Huh7 with IC50 values ranging from 2.3–37.8 µM [96]. Sep-
tosones A–C (301–303) were isolated from the sponge Dysidea septosa and septosone A 
(301) displayed good in vivo anti-inflammatory effects [97]. Terretonin N (304) (Figure 33) 
isolated from Nocardiopsis sp. illustrated a 15 mm of zone of inhibition towards Staphylo-
coccus warneri, which has been observed to be even higher than the reference drug, gen-
tamycin (14 mm) [98]. 
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Figure 33. Structures of sesquiterpene-based meroterpenoids 286–304. 
7. Chromane/Chromene and Flavone Derived Meroterpenoids 
Among other metabolites, the chromene-derived meroterpenoid with an additional 
furan ring within a prenyl moiety, tuberatolide B (305) (Figure 34), was initially reported 
from Botryllus tuberatus [99] and later from Sargassum macrocarpum [100]. This diastereo-
meric meroterpenoid is reported to display anticancer activity since it inhibits lung can-
cers (H1299 and A549), breast cancers (MDA-MB-453, MDA-MB-231, and MCF7), colon 
cancers (CT26, HCT116, and SW620), cervical cancer (HeLa), and prostate cancers (DU145 
and PC3) [100]. The mechanistic study revealed that compound 305 inhibits the growth of 
cancer cells by the production ROS in HCT116, A549, and MDA-MB-231, cells. It also in-
creases DNA damage by the formation of γH2AX foci and or the phosphorylation of Chk2 
and H2AX, which proteins are generally associated with DNA damage [100]. 
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Figure 34. Structures of chromane/chromene derived meroterpenoids 305–314. 
Chromane/chromene meroterpenoids (CMs), the rubiginosins A–G (306–312) (Figure 
34) and anthopogochromenes A (313) and B (314), were reported from Rhododendron ru-
biginosum [101]. In addition to spectroscopic techniques, their absolute structures were 
established by making use of the chromane/chromene helicity rule, X-ray crystallography 
and CD analysis. All these compounds were evaluated for their cytotoxic effects towards 
A549, HCT116, SK-HEP-1, and HL-60 (Table 4). Compound 310 was the most active 
against all cell lines with IC50 values of 10.91, 13.89, 11.71 and 7.40 μM, respectively and 
then followed compounds 306, 308 and 314. The other tested metabolites are reported to 
be inactive [101]. Doxorubicin (IC50 = 0.01–0.2 μM) was used as positive control in this 
study. Over 20 CMs have been reported from the genus Rhododendron bearing a canna-
binoid-like and orcinol core. Moreover, Rhododendron CM was also designated as a canna-
bicyclol (CBL)-type or cannabichromene (CBC)-type [102]. Interestingly CBC/CBL-type 
natural products having an orcinoid skeleton are rare in Cannabis and are mostly reported 
from Rhododendron species [102]. 
Sargassum siliquastrum produced a small library of the meroterpenoids isopolycera-
soidol (315), sargachromanols D (316), E (317), G (318), I (319), S (320), and T (321) (Figure 
35) and all were evaluated for their antioxidant effects. Compound 315 was the most ac-
tive in DPPH and ABTS antioxidant assays with EC50 values of 8.23 and 2.33 μM, respec-
tively [103]. Compounds 316–318 were weakly active against the DPPH free radical, but 
induced significant inhibition (EC50: 4.0 to 4.8 μM, Table 4) against the ABTS free radical. 
On the other hand, compounds 316 and 317 are only weakly active in DPPH and ABTS 
antioxidant assays with EC50 values ranging from 15.7 to 57.0 μM. The structure and ac-
tivity variation of compounds 316–318 suggest that the hydroxyl group at C-13 in the 
prenyl moiety can be the activity determining factor, since compounds 316 and 317 have 
the hydroxyl group at C-12, while compounds 318 and 319 have a corresponding keto 
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function. Other literature results show that the chromene nucleus is an important group 
for antioxidant activities [103]. 
 
Figure 35. Structures of chromane/chromene derived meroterpenoids 315–321. 
Table 4. Sesquiterpene-based, chromane/chromene and flavone derived meroterpenoids. 
Compounds Source Activities Ref. 
Langcoquinone A (248) Spongia sp. 
Antimicrobial effects: Staphylococcus aureus = MIC 12.5 μM; Bacil-
lus subtilis = MIC 12.5 μM 
[82] 
Langcoquinone B (249) Spongia sp. 
Antimicrobial effects: Staphylococcus aureus = MIC 12.5 μM; Bacil-
lus subtilis = MIC 12.5 μM 
[82] 
Langconol A (250)  Antimicrobial effects: B. subtilis MIC 12.5 μM [83] 
Langconol C (252)  Antimicrobial effects: B. subtilis = MIC 25.0 μM [83] 
Langcoquinone C (253)  
Antimicrobial effects: Staphylococcus aureus = MIC 12.50 μM; Ba-
cillus subtilis = MIC 6.25 μM 
[83] 
Aminoquinone (257) Dysidea sp. 
Antimicrobial effects: B. subtilis = MIC 50.0 μg/mL; S. aureus = 
MIC 50.0 μg/mL; E. coli = MIC 50.0 μg/mL 
[84] 
Nakijinol G (267) Hyrtios sp. Enzyme Inhibition: PTP1B = IC50 4.8 μM [87] 
Dysivillosin A (270) Dysidea villosa Enzyme Inhibition: β-hexosaminidase = IC50 8.2 μM [88] 
Dysivillosin B (271)  Enzyme Inhibition: β-hexosaminidase = IC50 10.2 μM [88] 
Dysivillosin C (272)  Enzyme Inhibition: β-hexosaminidase = IC50 19.9 μM [88] 
Dysivillosin D (273)  Enzyme Inhibition: β-hexosaminidase = IC50 16.2 μM [88] 
Chartarolide A (274) Niphates recondite 
Cytotoxic effects: HCT-116 = IC50 1.9 μM; HepG2 = IC50 1.8 μM; 
BGC-823 = IC50 1.3 μM; NCI-H1650 = IC50 5.5 μM; A2780 = IC50 1.5 
μM; MCF7 = IC50 1.4 μM 
[90] 
Chartarolide B (275) Niphates recondite 
Cytotoxic effects: HCT-116 = IC50 2.3 μM; HepG2 = IC50 2.8 μM; 
BGC-823 = IC50 1.6 μM; NCI-H1650 = IC50 4.8 μM; A2780 = IC50 3.2 
μM; MCF7 = IC50 3.8 μM 
[90] 
Chartarolide C (276) Niphates recondite 
Cytotoxic effects: HCT-116 = IC50 7.8 μM; HepG2 = IC50 8.9 μM; 
BGC-823 = IC50 5.4 μM; NCI-H1650 = IC50 11.3 μM; A2780 = IC50 
12.5 μM; MCF7 = IC50 8.7 μM 
[90] 
Terretonin N (304) Nocardiopsis sp. 
Antimicrobial effects: S. warneri = IZ 14 mm 
E. coli = IZ 8 mm 
[98] 
Rubiginosin A (306) Rhododendron rubiginosum 
Cytotoxic effects: A549 = IC50 16.15 μM; HCT116 = IC50 15.56 μM; 
SK-HEP-1 = IC50 13.80 μM; HL-60 = IC50 12.84 μM 
[101] 
Rubiginosin B (307) Rhododendron rubiginosum 
Cytotoxic effects: HCT116 = IC50 65.72 μM; SK-HEP-1 = IC50 84.66 
μM 
[101] 
Rubiginosin C (308) Rhododendron rubiginosum 
Cytotoxic effects: A549 = IC50 40.45 μM; HCT116 = IC50 17.43 μM; 
SK-HEP-1 = IC50 26.26 μM; HL-60 = IC50 16.44 μM 
[101] 
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Rubiginosin D (309) Rhododendron rubiginosum 
Cytotoxic effects: A549 = IC50 49.18 μM; HCT116 = IC50 32.17 μM; 
SK-HEP-1 = IC50 13.66 μM; HL-60 = IC50 40.07 μM 
[101] 
Rubiginosin E (310) Rhododendron rubiginosum 
Cytotoxic effects: A549 = IC50 38.90 μM; HCT116 = IC50 38.90 μM; 
SK-HEP-1 = IC50 38.90 μM; HL-60 = IC50 38.90 μM 
[101] 
Rubiginosin F (311) Rhododendron rubiginosum 
Cytotoxic effects: A549 = IC50 38.90 μM; HCT116 = IC50 38.90 μM; 
SK-HEP-1 = IC50 38.90 μM; HL-60 = IC50 38.90 μM 
[101] 
Rubiginosins G (312) Rhododendron rubiginosum 
Cytotoxic effects: A549 = IC50 38.90 μM; HCT116 = IC50 38.90 μM; 
SK-HEP-1 = IC50 38.90 μM; HL-60 = IC50 38.90 μM 
[101] 
Anthopogochromene A (313) Rhododendron rubiginosum 
Cytotoxic effects: A549 = IC50 38.90 μM; HCT116 = IC50 38.90 μM; 
SK-HEP-1 = IC50 38.90 μM; HL-60 = IC50 38.90 μM 
[101] 
Anthopogochromene B (314) Rhododendron rubiginosum 
Cytotoxic effects: A549 = IC50 38.90 μM; HCT116 = IC50 38.90 μM; 
SK-HEP-1 = IC50 38.90 μM; HL-60 = IC50 38.90 μM 
[101] 
Isopolycerasoidol (315) Sargassum siliquastrum Antioxidant effects: DPPH = EC50 8.23 μM; ABTS = EC50 2.33 μM [103] 
Sargachromanol D (316) Sargassum siliquastrum Antioxidant effects: DPPH = EC50 26.35 μM; ABTS = EC50 4.84 μM [103] 
Sargachromanol E (317) Sargassum siliquastrum Antioxidant effects: DPPH = EC50 23.84 μM; ABTS = EC50 4.57 μM [103] 
Sargachromanol G (318) Sargassum siliquastrum Antioxidant effects: DPPH = EC50 33.43 μM; ABTS = EC50 4.05 μM [103] 
Sargachromanol I (319) Sargassum siliquastrum Antioxidant effects: DPPH = EC50 32.83 μM; ABTS = EC50 6.86 μM [103] 
Another medicinal plant, Rhododendron capitatum produces enantiomeric pairs of 
meroterpenoids, the ()-rhodonoids C–G (322–326) (Figure 36). These compounds existed 
as racemates and were subsequently purified via chiral HPLC. Moreover, only 322a in-
hibited HSV-1 with an IC50 value of 80.6 µM. Compounds 322a and 322b featured the 
unusual 6/6/6/5 tetracyclic ring core while compounds 323a and 323b bore the rather rare 
6/6/5/5 tetracyclic ring system [104]. Another Rhododendron sp., viz., R. nyingchiense inter-
estingly, also produced enantiomeric pairs of the meromonoterpenoids 327a,b–332a,b and 
all racemic mixtures were separated by chiral-phase HPLC. These compounds possess 
PTP1B inhibition with IC50 values ranging from 29 to 61 μM. Compounds 327a,b feature 
a quite rare 6/6/5 tricyclic ring core [105]. 
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Figure 36. Structures of chromane/chromene derived meroterpenoids 322–332. 
Sargachromenol (333) (Figure 37) was produced by Sargassum serratifolium and inhib-
ited BChE and BACE1 with values for IC50: 9.4 and 7.0 μM respectively [106], while the 
reference compounds used were berberine (IC50 = 9.4 µM) and quercetin (IC50 = 5.6 µM) 
respectively. The alga Cystoseira baccata produced racemic mixtures of two meroterpe-
noids, tetraprenyltoluquinol (334a,b), and tetraprenyltoluquinone (335a,b). The in vitro 
anti-leishmanial study demonstrated that compound mixture 334a,b exhibited reasonable 
effects towards Leishmania infantum with IC50: 44.9 μM, whereas compound mixture 
335a,b was found to be a weak inhibitor with IC50 of 94.4 μM. In an SAR study, it was 
determined that the C-1 ketone decreases the anti-leishmanial effects since the difference 
between these two compounds viz., 334 and 335 is the keto group [107]. 
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Figure 37. Structures of chromane/chromene derived meroterpenoids 333–341. 
Diplomeroterpenoids A–F (336–341) (Figure 37), were isolated from the roots of Mi-
mosa diplotricha and featured the diterpenoid unit and chromen-4-one framework. Com-
pounds 336–338 and 340 inhibited protein farnesyl transferase (PFTase) with an IC50 rang-
ing from 5.0 to 8.5 μM [108]. Activity of the reference inhibitor FTase inhibitor II is re-
ported as IC50 = 0.1 µM. Additionally, diplomeroterpenoid A (336) is also reported to in-
hibit the growth of HepG2 cancer cells with a GI50: 8.6 μM. 
Glabralides C (342) was isolated from Sarcandra glabra [109]. Five pure meroterpenoid 
enantiomers (343a/343b–347a/347b) were produced by Rhododendron fastigiatum. Moreo-
ver, meroterpenoids 344a/344b, 345a/345b, demonstrated PTP1B inhibitory effects with 
IC50 ranging from 40.9 to 47.0 [110]. (+)-/(−)-Anthoponoids A–G, (348–354) (Figure 38), and 
(+)/(−)-daurichromene D (355) were isolated from Rhododendron anthopogonoides and (+)-
anthoponoid E (352a), (−)-anthoponoid G (354b), exhibited potent anti-inflammatory ef-
fects in RAW 264.7 macrophages [111]. 
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Figure 38. Structures of chromane/chromene derived meroterpenoids 342–354. 
Psocorylins A–J (356–365) (Figure 39) were produced by Psoralea corylifolia and eval-
uated for their cytotoxic effects towards HepG2, NCI-N87, HeLa, HCT-116, and B16-F10. 
Meroterpene 357 displayed remarkable cytotoxic effects towards these five cell lines with 
IC50: <10 μM. On the other hand, compounds 358–360 also illustrated significant effects 
towards HepG2 and NCI-N87 with IC50: < 10 μM, which demonstrated selectivity towards 
these two cancer cells. Compound 356 illustrated no cytotoxicity but indicated the de-
creased cytotoxic effects due to the presence of a methoxy group at C-7. Notably, com-
pound 361 displayed potent cytotoxic effects towards HepG2, NCI-N87, HeLa, and HCT-
116 with IC50 values from 1.82 to 5.74 μM, respectively [112]. Belamcandanins A–C (366–
368), were isolated from Belamcanda chinensis [113]. The highly functionalized, flavonoid-
derived triterpene saponin meroterpenoids, clinoposides G (369) and H (370) (Figure 39) 
were isolated from Clinopodium chinense. Both compounds featured a triterpenoid core 
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linked to a flavonoid framework via a C-C bond. The cardioprotective effects of com-
pounds 369 and 370 were evaluated and both compounds illustrated protective effects 
towards anoxia/reoxygenation(A/R)-induced injury in H9c2 cells [114]. 
 
Figure 39. Structures of chromane/chromene and flavone derived meroterpenoids 356–370. 
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8. Quinone-Based Meroterpenoids 
Streptomyces sp. produced naphthoquinone based meroterpenoids described as 
naphthablins B (371) and C (372) (Figure 40) and the absolute structures of these com-
pounds were established by ECD spectra and the TDDFT approach. Compounds 371 and 
372 were reported to be weakly active towards HeLa cells (19 to 32%) [115]. Magterpenoid 
C (373) was reported from Magnolia officinalis var. and illustrated significant PTP1B inhi-
bition with an IC50 value of 0.81 μM [116]. 
 
Figure 40. Structures of quinone-based meroterpenoids 371–373. 
In 2018, arnebinone B (374), compound 375, arnebifuranone (376), and arnebinone 
(377) (Figure 41) were isolated from Arnebia euchroma and tested against various liver can-
cer cell lines viz., SMMC-7721, HepG2/ADM HepG2, and QGY-7703. Compound 375 was 
the most active among all the tested cell lines with IC50 values ranging from 3.43 to 11.31 
μM, while compound 374 had IC50 values ranging from 9.6 to 18.7 μM. These activites are 
reported even higher than the activity of the reference drug Cisplatin (IC50 = 5.66–27.96 
μM). On the other hand, the activities of compounds 376 and 377 were not that impressive 
(Table 5) [117]. Meroterpneoid 375 was also reported but with a different name viz., JNU-
144, from Lithospermum erythrorhizon as a new compound in the same year (2018). The 
present study seems interesting in the sense that compound 375 has been reported to sup-
press cell viability and proliferation in hepatoma cells [118]. Toluquinol-derived mero-
terpenoid (378) bearing a tetraprenyl moiety, was isolated from the Carteriospongia sp. and 
was subsequently shown to trigger MMP disruption and apoptosis in lymphoma (U937 
and Sup-T1 cells), leukemia (Molt 4 and HL60 cells), oral (Ca9-22 and Cal-27 cells), breast 
(T-47D cells) with IC50 values ranging from 0.33 to 1.06 μg/mL [119]. Doxorubicin, a posi-
tive control displayed IC50 values in the range of 0.1–2.47 μg/mL, which revealed that the 
test compounds are equally active against the cell lines. Sargaquinoic acid (379) was re-
ported from Sargassum serratifolium and inhibited the activity of AChE, BChE and BACE1, 
(Table 5) with IC50 values of 69.3, 10.5, and 12.1 μM respectively [106]. 
 
Figure 41. Structures of quinone-based meroterpenoids 374–379. 
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Two naphthoquinone based meroterpenes named Flaviogeranin B (380) and Fla-
viogeranin D (381) (Figure 42) were produced by Streptomyces sp. Notably, compound 381 
illustrated significant antibacterial effects towards Mycobacterium smegmatis and Staphylo-
coccus aureus with MIC values ranging from 5.2 to 9.2 µg/mL. In addition, compound 381 
also possessed potent cytotoxic effects towards HeLa and A549 with IC50: 0.4 and 0.6 µM, 
respectively [120]. In another report Streptomyces sp. also produce merochlorins E (382) 
and F (383) which exhibited significant antibacterial effects towards B. subtilis, S. aureus, 
K. rhizophila with MIC ranging from 1–2 μg/mL [121]. 
 
Figure 42. Structures of quinone-based meroterpenoids 380–383. 
9. Miscellaneous 
Sargahydroquinoic acid (384) (Figure 43) was isolated from Sargassum serratifolium 
and inhibited BChE and BACE1 with values of IC50: 15.2 and 4.4 μM respectively [106]. 
Compared to the reference drugs berberine (IC50 = 9.4 µM) and quercetin (IC50 = 5.6 µM), 
respectively, the activities of these natural products are significant. Martucci et al. studied 
anticancer properties of tetronasin (385) which was obtained from Streptomyces sp. CP26-
58 by HRLCMS. Tetronasin (385) killed the HeLa cells with an IC50 value of 0.23 μM [115]. 
 
Figure 43. Structures of miscellaneous meroterpenoids 384 and 385. 
Magterpenoids A (386) and B (387) (Figure 44) were purified from the bark extract of 
Magnolia officinalis and tested for PTP1B inhibitory activities. Compound 386 displayed a 
significant inhibition of the enzyme with an IC50 value of 1.44 μM, which is higher than 
the positive control drugs donepezil (45.3% and 46.2%). Moreover magterpenoid A (386) 
featured an interesting 4,6,11-trioxatricyclo[5.3.1.01,5]undecane skeleton while compound 
387 had a 6/6/6/6 tetracyclic core [116]. Nyingchinoids A (388a,b) and B (389a,b) were sep-
arated from the plant Rhododendron nyingchiense. Metabolites 388a/b and 389a,b featured 
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6/7/5/5 and 6/6/3/5 heterocyclic ring frameworks respectively. Notably, compounds 
388a/b and 389a,b illustrated PTP1B effects with IC50 values of 43.6 and 38.1 µM, respec-
tively. In this assay, oleanolic acid was used as positive control, which showed an IC50 
value of 2.5 μM [105]. 
 
Figure 44. Structures of miscellaneous meroterpenoids 386–389. 
O-Spirocyclic ether analogs viz., 390 and 391 along with butanolide (392) (Figure 45) 
were obtained from Villorita cyprinoides, which is a traditional seafood in the coastal re-
gions of the Arabian Sea. Meroterpenoid 391 illustrated activity towards COX-1 (IC50: 0.86 
mg/mL) and COX-2 (IC50: 0.65 mg/mL) enzymes, followed by compound 390 (COX-1: IC50: 
0.94 mg/mL; COX-2: IC50: 0.70 mg/mL) [122]. On the other hand, compound 392 was also 
found to be active towards COX-1 (IC50: 0.91 mg/mL) but slightly less active than COX-2 
(IC50: 0.74 mg/mL) when compared to compound 390 and 391. Further biological studies 
revealed that compounds 390–392 demonstrated 5-LOX inhibitory effects (IC50 = 0.77, 0.75, 
0.80 mg/mL, respectively and their effects were higher than the standard ibuprofen (IC50 
= 0.96 mg/mL). In addition, these meroterpenoids illustrated more potent selectivity indi-
ces (SI: IC50: 1.23–1.34) than ibuprofen (SI: IC50: 0.63). Meroterpenoids 390 (IC50: 0.59 
mg/mL) and 391 (IC50: 0.54 mg/mL) possess potent DPPH antioxidant effects which are 
higher than the standard α-tocopherol (IC50 = 0.65 mg/mL). Of note, compound 392 illus-
trated slightly less activity (IC50 = 0.69 mg/mL) than the previous two compounds [122]. 
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Figure 45. Structures of miscellaneous meroterpenoids 390–396. 
Villorita cyprinoides also produces four meroterpenoids viz., 393–396 (Figure 45) 
which were evaluated for various biological effects. Meroterpenoids 393–396 illustrated 
potent effects towards COX-1 and COX-2 in which the IC50: ranged from 0.84 to 1.09 
mg/mL [123], while the positive control ibuprofen exhibited IC50 values of 0.05 and 0.08 
mg/mL, respectively. Additionally, these compounds possess anti-COX-1/anti-COX-2 ac-
tivity with IC50: ranging from 1.12 to 1.22 mg/mL (Table 5). On the other hand, meroterpe-
noids 393–396 also display significant anti-5-LOX potential effects with IC50 values rang-
ing from 0.76 to 0.98 mg/mL with the effects of 393 (IC50 = 0.92 mg/mL) and 394 (IC50 = 0.76 
mg/mL) being higher than the standard ibuprofen (IC50 = 0.96 mg/mL). Furthermore, mer-
oterpenoids 393–396 also displayed DPPH antioxidant effects with IC50 values ranging 
from 0.63 to 0.79 mg/mL [123]. 
Erlotinib, the reference drug in this study, showed IC50 values of 4.5 and 7.66 µM, 
respectively. Meroterpenoids, 2-[tetrahydro-5-(4-hydroxyphenyl)-4-pentylfuran-3-yl]-
ethyl-4-hydroxybenzoate (397), 2-2-[(4-hydroxybenzoyl)-oxy]-ethyl-4-methoxy-4-2-[(4-
methylpentyl)oxy]-3,4-dihydro-2H-6-pyranylbutanoic acid (398) and 3-[(5-butyl-3-me-
thyl-5,6-dihydro-2H-pyran-2-yl)-methyl]-4-methoxy-4-oxobutyl benzoate (399) (Figure 
46) were reported from the alga Hypnea musciformis and were evaluated for their antioxi-
dant effects. Compound 397 was more potent in terms of its DPPH radical effect (IC50: 25.0 
μM) and this activity was higher than the standard gallic acid. On the other hand, com-
pounds 398 (IC50: 322.4.0 μM) and 399 (IC50: 231.2 μM) exhibit quite low antioxidant activ-
ity [124]. 
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Figure 46. Structures of miscellaneous meroterpenoids 397–399. 
Cystoseira usneoides produces the meroterpenoids; cystodiones G–J (400–403), L (404) 
and M (405) along with cystones A–F (406–411) (Figure 47) [125]. All these compounds 
featured the toluhydroquinone core attached to a diterpenoid moiety. Compounds 400–
411 illustrated radical-scavenging effects which ranged from 37% to 87%. Among these 
compounds, cystodiones G (400; 81%) and H (401; 77%) were the most potent. Moreover, 
cystodione G (400) and cystodione M (405) significantly inhibited the TNF-α production 
with 81% and 79% respectively while cystone C (408) demonstrated a moderate inhibition 
of 59% [125]. 2-[(E)-Deca-1,8-dien-10-yl]-11,12-dihydro-13-propyl-2H-pyran (412) and 1′-
[(10E)-10-{10-pentan-4-yl}-cyclohex-4-enyl]-allyloxy)-tetrahydro-2′, 2′-dimethyl-2H-py-
ran (413) (Figure 47) were reported to be isolated from an animal source viz., Paphia mala-
barica [126]. In the DPPH antioxidant assay, compound 413 was slightly more potent (IC50 
= 0.76 mg/mL) than compound 412 (IC50 = 0.78 mg/mL), while in the ABTS evaluation, 
compound 412 (IC50 = 0.92 mg/mL) was slightly more active than compound 413 (IC50 = 
0.96 mg/mL). In addition both compounds were active towards COX-1 and COX-2 (IC50: 
0.92 to 1.07 mg/mL) along with selectivity indices of ~1.1 mg/mL. Moreover compounds 
412 (IC50 = 1.02 mg/mL) and 413 (IC50 = 1.06 mg/mL) illustrated 5-LOX inhibition effects 
[126]. 
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Figure 47. Structures of miscellaneous meroterpenoids 400–413. 
The meroterpenoid enantiomers, (±)-rasumatranin A–D (414–417) and (±)-radulanin 
M (418) and N (419) along with meroterpenoids 420, 421 and (±)-radulanin I (422) (Figure 
48) were isolated from Radula sumatrana [127]. Compounds 414–417 and 421 (Figure 48) 
are monoterpene-bibenzyl hybrid metabolites while 421 and 422 are hemiterpenoid-
bibenzyl hybrid compounds. Among these compounds, 421 proved to be very potent to-
wards MCF-7 (IC50: 3.8 µM), PC-3 (IC50: 6.6 µM) and SMMC-7721 7 (IC50: 3.5 µM) while 
422 was only moderatively active towards these cancer cells with IC50 values 13.9–19.5 
µM. On the other hand compounds 415 and 422 demonstrated moderate effects towards 
MCF-7 with IC50: 38.3 and 24.6 µM respectively [127]. 
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Figure 48. Structures of miscellaneous meroterpenoids 414–422. 
Meroindenon (423) was isolated from Streptomyces and illustrated moderate antimi-
crobial effects towards B. subtilis, K. rhizophila, and S. aureus [121]. Hyperinoids A (424) 
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and B (425) (Figure 49) were isolated from Hypericum patulum and both compounds sig-
nificantly inhibited NF-kB in RAW 246.7 macrophages [128]. Meroterpenoids 426 and 427 
were produced by the mushroom Panus lecomtei [129] and prenylbruceol A was isolated 
from Philotheca myoporoides [130]. Moreover 6-deoxytolypodiol (428) and 11-hydroxytoly-
podiol (429) were produced by cyanobacterial sources. Only compound 430 displayed po-
tent anti-inflammatory effects with IC50: 0.1 µM while the same compound possessed sim-
ilar levels of TXB2 inhibitory effects as NSAID flurbiprofen [131]. Hyperprins A (431) and 
B (432) were produced by Hypericum przewalskii and both compounds featured a 
6/6/6/6/5/5 hexacyclic core and a 6/8/6/6 tetracyclic system respectively [132]. In another 
report hypulatones A (433) and B (434) (Figure 49) were produced by Hypericum patulum 
and the latter compound remarkably inhibited the late current of Nav1.5 with IC50: 0.2 μM) 
[133]. 
 
Figure 49. Structures of miscellaneous meroterpenoids 423–434. 
Biomolecules 2021, 11, 957 49 of 56 
 
Ampechromonol A (435) and B (436) (Figure 50) were produced by Ampelopsis can-
toniensis and displayed weak cytotoxic effects towards MCF-7 cells [134]. Psoralea corylifo-
lia seed produced 7β, 13β-psoracorylifol B (437) and 7β, 8α-psoracorylifol D (438). Moreo-
ver, compounds 435–439 displayed moderate inhibitory effects towards DGAT1 with IC50: 
67.1 and 99.5 μM, respectively. On the other hand, both compounds 435 and 436 illus-
trated weak inhibition towards DGAT2 with IC50: 132.9 and 134.2 μM, respectively [135]. 
In another report, corypsoriols A–N (439–452) (Figure 50) were isolated from Psoralea cor-
ylifolia [136]. 
 
Figure 50. Structures of miscellaneous meroterpenoids 435–452. 
Table 5. Sources and biological effects of meroterpenoids 373–422. 
Compounds Source Activities Ref. 
Magterpenoid C (373) Magnolia officinalis Enzyme inhibition: PTP1B = IC50 0.81 μM [116] 
Arnebinone B (374) Arnebia euchroma 
Cytotoxic effects: HepG2, SMMC-7721, QGY-7703 and HepG2/ADM 
IC50 ranging from 9.6 to 18.7 μM 
[117] 
Compound 375 Arnebia euchroma 
Cytotoxic effects: HepG2, SMMC-7721, QGY-7703 and HepG2/ADM 
IC50 ranging from 3.43 to 11.31 μM 
[117] 
Toluquinol-derivative (378) Carteriospongia sp. 
Cytotoxic effects: Molt 4 = IC50 0.34 μg/mL; HL60 = IC50 0.70 μg/mL; 
lymphoma U937 = IC50 0.65 μg/mL; Sup-T1 = IC50 0.33 μg/mL; oral Ca9-
22 = IC50 0.97 μg/mL; Cal-27 = IC50 0.51 μg/mL; breast T-47D = IC50 1.06 
μg/mL 
[119] 
Sargaquinoic acid (379) Sargassum serratifolium 
Enzyme inhibition: AChE = IC50 69.3 μM; BChE = IC50 10.5 μM; BACE1 
= IC50 12.1 μM 
[106] 
Sargahydroquinoic acid (384) Sargassum serratifolium 
Enzyme inhibition: AChE = IC50 124.3 μM; BChE = IC50 15.2 μM; BACE1 
= IC50 4.4 μM 
[106]  
Tetronasin (385) Streptomyces sp. Cytotoxic effects: HeLa cells = IC50 0.23 μM [115] 
Magterpenoid A (386) Magnolia officinalis Enzyme inhibition: PTP1B = IC50 1.44 μM [116] 
Nyingchinoids A (388a,b) 
Rhododendron 
nyingchiense 
Enzyme inhibition: PTP1B = IC50 43.6 μM [105] 
Nyingchinoids B (389a,b) 
Rhododendron 
nyingchiense 
Enzyme inhibition: PTP1B = IC50 38.1 μM [105] 
Compound 390 Villorita cyprinoides 
Antioxidant effects: DPPH = IC50 0.59 mg/mL; ABTS = IC50 0.65 mg/mL; 
Enzyme inhibition: COX-1 = IC50 0.94 mg/mL; COX-2 = IC50 0.70 mg/mL 
[122] 
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Compound 391 Villorita cyprinoides 
Antioxidant effects: DPPH = IC50 0.54 mg/mL; ABTS = IC50 0.62 mg/mL; 
Enzyme inhibition: COX-1 = IC50 0.86 mg/mL; COX-2 = IC50 0.65 mg/mL 
[122] 
Compound 392 Villorita cyprinoides 
Antioxidant effects: DPPH = IC50 0.69 mg/mL; ABTS = IC50 0.64 mg/mL; 





Antioxidant effects: DPPH = IC50 0.70 mg/mL; ABTS = IC50 0.76 mg/mL; 
Fe2+ = IC50 0.83 mg/mL; H2O2 = IC50 0.85 mg/mL; COX-1 = IC50 0.99 






Antioxidant effects: DPPH = IC50 0.63 mg/mL; ABTS = IC50 0.79 mg/mL; 
Fe2+ = IC50 0.83 mg/mL; H2O2 = IC50 0.84 mg/mL; Enzyme inhibition: 





Antioxidant effects: DPPH = IC50 0.76 mg/mL; ABTS = IC50 0.82 mg/mL; 
Fe2+ = IC50 0.90 mg/mL; H2O2 = IC50 0.86 mg/mL; Enzyme inhibition: 





Antioxidant effects: DPPH = IC50 0.79 mg/mL; ABTS = IC50 0.81 mg/mL; 
Fe2+ = IC50 0.89 mg/mL; H2O2 = IC50 0.87 mg/mL; Enzyme inhibition: 











hydro-2H-6-pyranylbutanoic acid (398) 
Hypnea musciformis 







Antioxidant effects: DPPH = IC50 231.2 μM  





Antioxidant effects: DPPH = IC50 0.78 mg/mL; ABTS = IC50 0.92 mg/mL; 
Enzyme inhibition: COX-1 = IC50 1.07 mg/mL; COX-2 = IC50 0.95 






Antioxidant effects: DPPH = IC50 0.76 mg/mL; ABTS = IC50 0.96 mg/mL; 
Enzyme inhibition: COX-1 = IC50 1.05 mg/mL; COX-2 = IC50 0.92 
mg/mL; 5-LOX = IC50 1.06 mg/mL 
[126] 
(±)-Rasumatranin B (415) Radula sumatrana Cytotoxic effects: MCF-7 = IC50: 38.3 µM [127] 
Compound 421 Radula sumatrana 
Cytotoxic effects: MCF-7: IC50: 3.8 µM; PC-3: IC50: 6.6 µM; SMMC-7721 
7: IC50: 3.5 µM 
[127] 
(±)-Radulanin I (422) Radula sumatrana Cytotoxic effects: MCF-7 = IC50: 24.6 µM [127] 
10. Conclusions 
In this review, the structures, chemical diversity, and biological properties of 452 new 
meroterpenoids have been reported. The chemical structures of meroterpenoids are ex-
tremely diverse, as may be noted by the various biosynthetic pathways and clearly 
demonstrated nature’s sophisticated synthetic protocols to generate this tremendous 
chemical diversity via simple and achiral starting units. As comprehensively explored in 
each section, these types of secondary metabolites possess a tremendous structural diver-
sity resulting from such reactions as condensation, alkylation, oxidation, and reduction. 
Moreover, meroterpenoids incorporated multiple prenyl moieties or very complex ring 
cores, which furnish abundant molecular scaffolds for such a wide range of biological ac-
tivities. 
Due to their structural diversity, meroterpenoids illustrated a wide range of biologi-
cal and pharmacological activities, viz., antimicrobial, anticancer/cytotoxic, antioxidant, 
anti-inflammatory, antiviral immunosuppressive, and anti-Leishmania. Moreover, these 
compounds are also reported to possess important enzyme inhibitory effects, viz., acetyl-
cholinesterase, protein tyrosine phosphatase 1B (PTP1B), BACE1, dehydrogenase 1 
(IDH1), α-glucosidase, influenza neuraminidase, Janus Kinase 3 (JAK3), HMG-CoA, al-
dose reductase, maltase, and β-hexosaminidase. Among phloroglucinol-derived me-
troterpenoids, psiguajavadial B (2), which was isolated from Psidium guajava, illustrated 
potent cytotoxic effects towards lung cancer (A549) with IC50 0.90 µM. Moreover, eugenial 
C (18), which was produced by Eugenia umbelliflora, possessed significant cytotoxic effects 
towards leukemia cells (K562) with IC50 0.38 μM. On the other hand, Eucalyptus robusta 
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produced eucarobustols A (63), G (69), and I (71) and these compounds illustrated signif-
icant PTP1B inhibition (antidiabetic effects) with IC50 1.3, 1.8, and 1.6 μM, respectively. 
Among syncarpic acid/β-triketones-based meroterpenes, frutescones O (182) exhibited 
anti-inflammatory activity with an IC50 value of 0.36 μM while hyperjaponols B (195a) D 
(197) demonstrated potent antiviral effects towards the EBV virus with EC50 0.57 and 0.49 
μM respectively. 
Marinocyanin A (240) is an alkaloidal based meroterpenoid and is isolated from Ac-
tinomycete strains; it demonstrates potent cytotoxic effects towards colon cancer (HCT-
116) with IC50 0.049 μM. Furthermore, this compound also possesses significant antimi-
crobial effects towards Candida albicans (MIC: 0.95 μM), and Staphylococcus aureus (MIC: 
2.3 μM). Similarly, another alkaloidal based meroterpenoid marinocyanin B (241) also 
demonstrated potent cytotoxic effects towards HCT-116 with IC50 0.029 μM. Among ses-
quiterpene-based meroterpenoids, chartarolide A (274) was produced by Niphates recon-
dite and demonstrated significant cytotoxic effects towards HCT-116, HepG2, BGC-823, 
A2780, and MCF7 with IC50 1.9, 1.8, 1.3, 1.5, and 1.4 μM, respectively. Magterpenoid C 
(373) demonstrated potent antidiabetic effects (PTP1B = IC50 0.81 μM). Notably meroter-
pene 378 possessed potent cytotoxic effects towards Molt 4, HL60, lymphoma U937, Sup-
T1, oral Ca9-22, and with IC50 < 1.0 μg/mL. In addition, tetronasin (385) which was pro-
duced by Streptomyces sp., illustrated significant cytotoxic effects towards HeLa cells with 
IC50 0.23 μM. From the large library of bioactive meroterpenoids described in this detailed 
review, we hope a reasonable range of new lead structures may enter into the drug devel-
opment process to treat debillitating diseases in the future. 
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